William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
View Older Stories View More Recent Stories
-
William Blair Reiterates Market Perform Rating on Sprinklr Inc (CXM): "a lot to prove on the execution front"
-
William Blair: 'increasing likelihood that Oracle sees significant earnings growth acceleration over the coming years'
-
Dianthus Therapeutics prices $625 million public stock offering
-
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
-
Xenon Pharmaceuticals prices $650 million stock offering at $57 per share
-
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
-
William Blair Reiterates Outperform Rating on Veeva Systems (VEEV) amid Ostro acquisition
-
William Blair Reiterates Outperform Rating on Tenax Therapeutics (TENX): "continue to believe positive top-line results from LEVEL have the potential to drive multifold upside"
-
Medline completes $3.5 billion secondary stock offering
-
Medline Inc. announces closing of secondary offering of Class A common stock and full exercise of underwriters’ option to purchase additional shares
-
William Blair Reiterates Outperform Rating on Exagen (XGN) following Q4 results
-
William Blair Reiterates Outperform Rating on LENZ Therapeutics Inc (LENZ): "continue to believe VIZZ holds blockbuster potential"
-
Truelink Capital Closes Oversubscribed Fund II at $2.0 Billion Hard Cap
-
William Blair Reiterates Outperform Rating on Standex International (SXI) following meetings with management
-
William Blair Starts BridgeBio Pharma (BBIO) at Outperform
-
Analysis-Gabon's uncertain push for IMF loan leads regional return to Fund
-
MiniMed closes IPO raising $538 million at $20 per share
-
MiniMed announces closing of Initial Public Offering
-
William Blair Reiterates Outperform Rating on Nayax (NYAX) following earnings
-
William Blair Reiterates Outperform Rating on StoneX Group Inc. (SNEX): "current price looks highly attractive"
-
Dianthus Therapeutics announces $400 million public stock offering
-
Xenon Pharmaceuticals announces $500 million public offering
-
Xenon Pharmaceuticals Announces Proposed Public Offering
-
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
-
William Blair Reiterates Outperform Rating on Kalaris (KLRS): "we see blockbuster potential for TH103 in nAMD"
-
William Blair Reiterates Outperform Rating on Microsoft (MSFT) following product announcements
-
William Blair Reiterates Market Perform Rating on ULTA Beauty (ULTA) ahead of earnings
-
William Blair: 'We expect Microsoft to continue expanding its enterprise wallet share'
-
William Blair Reiterates Outperform Rating on Crawford & Company (CRD-B): "Significant upside is possible"
-
William Blair Reiterates Outperform Rating on Abbvie (ABBV): "competitive across the amylin class"
-
William Blair Downgrades TalkSpace (TALK) to Market Perform
-
William Blair Reiterates Outperform Rating on Xenon Pharmaceuticals (XENE): "we see further room for upside"
-
William Blair Reiterates Outperform Rating on Korn/Ferry (KFY) following Q3 results
-
William Blair Reiterates Outperform Rating on Dianthus Therapeutics (DNTH): "remain bullish here"
-
William Blair Reiterates Outperform Rating on ARS Pharmaceuticals Inc (SPRY) following Q4 results
-
William Blair: '$15 move in oil can cause FCF yield to more than double'
-
Korro Bio raises $85 million in oversubscribed private placement
-
Korro Announces Oversubscribed $85 Million Private Placement
-
William Blair Starts Jade Biosciences (JBIO) at Outperform
-
William Blair Reiterates Outperform Rating on Amprius Technologies (AMPX): "best-positioned arms dealer to supply this burgeoning industry"
-
William Blair Reiterates Outperform Rating on Stitch Fix, Inc. (SFIX): "Pullback Creates Compelling Entry Point"
-
Holding(s) in Company
-
William Blair Reiterates Outperform Rating on Crescent Energy (CRGY) following convertible notes offering announcement
-
William Blair Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Market Perform, Removed from Analyst Conviction List
-
William Blair: 'we believe Marvell is well positioned to grab its fair share of the AI infrastructure wallet'
-
SCHMID Group N.V. announces closing of the second tranche of its USD 30 million convertible notes financing
-
Ingram Micro prices secondary offering at $22.25 per share
-
Ingram Micro Holding Corporation Announces Pricing of Secondary Offering of Common Stock by its Principal Stockholder.
-
MiniMed prices IPO at $20 per share, raising $560 million
-
MiniMed announces pricing of initial public offering

